The antiphospholipid thrombosis syndromes: A common multidisciplinary medical problem

Clinical and Applied Thrombosis/Hemostasis

Volumn 3, Issue 4, 1997, Pages 270-283

  Bick, Rodger L ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b Dallas Thromb Hemostasis Vasc M   (United States)

Author keywords

Anticardiolipin antibody; Lupus anticoagulant; Thrombosis

Indexed keywords

ALPHA INTERFERON; CARDIOLIPIN ANTIBODY; COCAINE; FANSIDAR; HEPARIN; HYDRALAZINE; LUPUS ANTICOAGULANT; PHENOTHIAZINE DERIVATIVE; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PROCAINAMIDE; QUINIDINE; QUININE; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNITY; CLINICAL EXAMINATION; CLINICAL FEATURE; COLLAGEN DISEASE; DIAGNOSTIC ACCURACY; FETUS WASTAGE; HEART DISEASE; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; MEDICAL SPECIALIST; PRIORITY JOURNAL; SKIN DEFECT; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

EID: 0031409420     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602969700300409     Document Type: Article

References (143)

1. Bick RL, Ancypa D. Blood protein defects associated with thrombosis: Laboratory assessment. Clin Lab Med 1995;15:125.
2. Bick RL. Hypercoagulability and thrombosis. Med Clin North Am 1994;78:635.
3. Oosting JD, Derksen RH, Bobbink IWG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: An explanation for their pathogenic mechanism? Blood 1993;81:2618.
4. Bick RL, Baker WF. Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 1992;6:1287.
5. Bick RL. Lupus anticoagulants and anticardiolipin antibodies. Biomed Prog 1993;6:35.
6. Bick RL, Baker WF. The antiphospholipid and thrombosis syndromes. Med Clin North Am 1994;78:667.
7. Bowie EJW, Thompson JH, Pascuzzi CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulant. J Lab Clin Med 1963;162:417.
8. Shapiro SS, Thagarajan P. Lupus anticoagulants. Prog Hemost Thromb 1982;6:263.
9. Bell WR, Boss GR, Wolfson JS. Circulating anticoagulant in the procainamide-induced lupus syndrome. Arch Intern Med 1977; 137:1471.
10. Bick RL. The Antiphospholipid Thrombosis Syndromes: Lupus Anticoagulants & Anticardiolipin Antibody. In: Advances in pathology and laboratory medicine, Vol. 8. St. Louis: C.V. Mosby, 1995:391.
11. Espinoza LR, Hartmann RC. Significance of the lupus anticoagulant. Am J Hematol 1986;22:331.
12. Manoussakis MN, Tzioufas AG, Silis MP. High prevalence of anticardiolipin and other autoantibodies in a healthy elderly population, Clin Exp Immunol 1987;69:557.
13. Zarrabi MH, Zucker S, Miller F. Immunologic and coagulation disorders in chlorpromazine-treated patients. Ann Intern Med 1979;91:914.
14. Harris EN, Gharavi AE, Boey ML. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;II:1211.
15. Weidmann CE, Wallace D, Peter J. Studies of IgG, IgM and IgA antiphospholipid antibody isotypes in systemic lupus erythematosus. J Rheumatol 1988;15:74.
16. Bick RL, Baker WF. Antiphospholipid and thrombosis syndromes. Semin Thromb Hemost 1994;20:3.
17. Hughes GVR, Harris EN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986;13:486.
18. Asherson RA, Harris EN. Anticardiolipin antibodies: clinical associations. Postgrad Med J 1986;62:1081.
19. Bick RL. Antiphospholipid-Thrombosis Syndromes: Etiology, pathophysiology, diagnosis and management. Internat J Hematol 1997;65:193.
20. Bick RL, Laughlin HR, Cohen B, et al. Fetal wastage syndrome due to blood protein/platelet defects: Results of prevalence studies and treatment outcome with low-dose heparin and low-dose aspirin. Clin Appl Thromb Hemost 1995;1:286.
21. Derue G, Englert H, Harris E. Fetal loss in systemic lupus: Association with anticardiolipin antibodies. Br J Obstet Gynecol 1985;5:207.
22. Lubbe WF, Palmer SJ, Butler WS. Fetal survival after prednisolon suppression of maternal lupus anticoagulant. Lancet 1983;I:1361.
23. Rosove MH, Brewer P, Rungel A. Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids. Am J Hematol 1989;32:148.
24. McNeil HP, Chesterman CN, Krilis SA. Anticardiolipin antibodies and lupus anticoagulants comprise separate antibody subgroups with different phospholipid binding characteristics. Br J Haematol 1989;73:506.
25. Shi BS, Chong BH, Chesterman CN. Beta-2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants. Blood 1993;81:1255.
26. Harris EN, Hughes GRV, Gharavi AE. Antiphospholipid antibodies: an elderly statesman dons new garments. J Rheumatol 1987;14:208.
27. Gharavi AE, Harris EN, Asherson RA. Anticardiolipin antibodies: isotype distribution and phospholipid specificity. Ann Rheum Dis 1987:46:1.
28. Carreras L, Defreyn G, Manchin S. Arterial thrombosis, intrauterine death and lupus anticoagulant: Detection of immunoglobulin interfering with prostacyclin formation. Lancet 1981;I:244.
29. Cariou R, Tobelem G, Bellucci S. Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells: Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 1988;60:54.
30. Cosgriff TM, Martin BA. Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant. Arthritis Rheum 1981;24:94.
31. Khamashta MA, Harris EN, Gharavi AE. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 1988;47:849.
32. Sanfellipo MJ, Drayna CJ. Prekallikrein inhibition association with the lupus anticoagulant. Am J Clin Pathol 1982;77:275.
33. Roubey RAS. Autoantibodies to phospholipid-bonding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" antibodies. Blood 1994;84:2854.
34. Angeles-Cano E, Sultan Y, Clauvel JP. Predisposing factors to thrombosis in systemic lupus erythematosus. Possible relation-ship to endothelial cell damage. J Lab Clin Med 1979;94:312.
35. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 1992;117:997.
36. Boey ML, Colaco CB, Gharavi AE. Thrombosis in SLE: Striking association with the presence of circulating "lupus anticoagulant." Br Med J 1983;287:1021.
37. Elias M, Eldor A. Thromboembolism in patients with the "lupuslike" circulating anticoagulant. Arch Intern Med 1984;144:510.
38. Hall S, Buettner H, Luthra HS. Occlusive retinal vascular disease in systemic lupus erythematosus. J Rheumatol 1984;11:946.
39. Asherson RA, Harris EN, Gharavi AE. Arterial occlusions associated with antibodies to anticardiolipin [Abstract]. Arthritis Rheum 1985;28:S89.
40. Hamilton ME. Superior mesenteric artery thrombosis associated with antiphospholipid syndrome. West J Med 1991;155:174.
41. Asherson RA, Harris EN, Gharavi AE. Aortic arch syndrome associated with anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum 1985;28:594.
42. Asherson RA, Morgan SH, Harris EN. Arterial occlusion causing large bowel infarction: A reflection of clotting diathesis in SLE. Clin Rheumatol 1986;5:102.
43. Asherson RA, MacKay IR, Harris EN. Myocardial infarction in a young male with systemic lupus erythematosus deep vein thrombosis and antiphospholipid antibodies. Br Heart J 1986;56:190.
44. Gavaghan TP, Krilis SA, Daggard GE. Anticardiolipin antibodies and occlusion of coronary artery bypass grafts. Lancet 1987;II:977.
45. Morton KT, Gavaghan S, Krilis G. Coronary artery bypass graft failure: An autoimmune phenomenon? Lancet 1986;I:1353.
46. Hamsten A, Norberg R, Bjorkholm M. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events. Lancet 1986;I:113.
47. Harpaz D, Sidi Y. Successful thrombolytic therapy for acute myocardial infarction in a patient with the antiphospholipid antibody syndrome. Am Heart J 1991;122:1492.
48. Asherson RA, Khamashta MA, Ordi-Ros J. The "primary" antiphospholipid syndrome: Major clinical and serological features. Medicine 1989;68:366.
49. Bick RL, Ismail Y, Baker WF. Coagulation abnormalities in patients with precocious coronary artery thrombosis and patients failing coronary artery bypass grafting and percutaneous transcoronary angioplasty. Semin Thromb Hemost 1993;19:411.
50. Baker WF, Bick RL. Antiphospholipid antibodies in coronary artery disease. Semin Thromb Hemost 1994;20:27.
51. Galve E, Ordi J, Barquinero J. Valvular heart disease in the primary antiphospholipid syndrome. Ann Intern Med 1992;116:293.
52. Chartash EK, Lans DM, Paget SA. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 1989;86:406.
53. Chartash EK, Paget SA, Lockshin MD. Lupus anticoagulant associated with aortic and mitral valve insufficiency. Arthritis Rheum 1986;29:95.
54. Leung WH, Wong KL, Wong CK. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. Am J Med 1990;89:411.
55. Coppock MA, Safford RE, Danielson GK. Intracardiac thrombosis, phospholipid antibodies, and two-chambered right ventricle. Br Heart J 1988;60:455.
56. Reisner SA, Blumenfeld Z, Brenner B. Cardiac involvement in patients with primary antiphospholipid syndrome [Abstract]. Circulation 1990;82(suppl III):398.
57. Weinstein C, Miller M, Axtens R. Livido reticularis associated with increased titers of anticardiolipin antibodies in systemic lupus erythematosus. Arch Dermatol 1987;123:596.
58. Eng AM. Cutaneous expressions of antiphospholipid syndromes. Semin Thromb Hemost 1994;20:71.
59. Englert H, Hawkes C, Boey M. Dagos' Disease: Association with anticardiolipin antibodies and the lupus anticoagulant. Br Med J 1984;289:576.
60. Wolf P, Peter-Soyer H, Auer-Grumbach P. Widespread cutaneous necrosis in a patient with rheumatoid arthritis associated with anticardiolipin antibodies. Arch Dermatol 1991;127:1739.
61. Ingram SB, Goodnight SH, Bennett RM. An unusual syndrome of a devastating non-inflammatory vasculopathy associated with anticardiolipin antibodies: Report of two cases. Arthritis Rheum 1987;30:1167.
62. Levine SR, Langer SL, Albers JW. Sneddon's syndrome: An antiphospholipid antibody syndrome? Neurology 1988;38:798.
63. Frampton G, Winer JB, Cameron JS. Severe Guillain-Barre' syndrome: An association with IgA anti-cardiolipin antibody in a series of 92 patients. J Neuroimmunol 1988;19:133.
64. Levine S, Welch K. The spectrum of neurologic disease associated with anticardiolipin antibodies. Arch Neurol 1987;44:876.
65. Oppenheimer S, Hoffbrand B. Optic neuritis and myelopathy in systemic lupus erythematosus. Can J Neurol Sci 1986;13:129.
66. Harris EN, Gharavi AE, Asherson RA. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984;2:47.
67. Williams RC. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin Exp Rheumatol 1984;2:3.
68. Coull BM, Bourdette DN, Goodnight SH. Multiple cerebral infarctions and dementia associated with anticardiolipin antibodies. Stroke 1987;18:1107.
69. Hinton RC. Neurological syndromes associated with antiphospholipid antibodies. Semin Thromb Hemost 1994;20:46.
70. Asherson RA, Khamashta MA, Hughes GRV. Sneddon's syndrome, [letter]. Neurology 1989;39:1138.
71. Moral A. Sneddon's syndrome with antiphospholipid antibodies and arteriopathy. Stroke 1991;22:1327.
72. Sohngen D, Wehmeier A, Specker C. Antiphospholipid antibodies in systemic lupus erythematosus and Sneddon's syndrome. Semin Thromb Hemost 1994;20:55.
73. Levine SR, Brey RL, Joseph CLM. Risk of recurrent thromboembolic events in patients with focal cerebral ischemia and antiphospholipid antibodies. Stroke 1992;23(suppl I):29.
74. Levine SR, Diaczok IM, Deegan MJ. Recurrent stroke associated with thymoma and anticardiolipin antibodies. Arch Neurol 1987; 44:678.
75. Hull RG, Harris N, Gharavi AE. Anticardiolipin antibodies: occurrence in Behcet's syndrome. Ann Rheum Dis 1984;43:746.
76. Harris EN, Gharavi AE, Hedge U. Anticardiolipin antibodies in autoimmune thrombocytopenia purpura. Br J Haematol 1985;59: 231.
77. Kampe CE. Clinical syndromes associated with lupus anticoagulants. Semin Thromb Hemost 1994;20:16.
78. Harris NE, Spinnato JA. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991;165:1272.
79. Buchanan NM, Khamashta MA, Morton KE, et al. A study of 100 high-risk lupus pregnancies. Am J Reprod Immunol 1992;28:192.
80. Anticardiolipin antibodies: A risk factor for venous and arterial thrombosis [Editorial]. Lancet 1985;I:912.
81. Kwak JY, Gilman-Sachs A, Beaman KD, et al. Reproductive outcome in women with recurrent spontaneous abortions of alloimmune and autoimmune causes: Preconception versus postconception treatment. Am J Obstet Gynecol 1992;166:1787.
82. Lin QD. Investigation of the association between autoantibodies and recurrent abortions. Clin J Obstet Gynecol 1993;28:674.
83. Parazzini F, Acaia B, Faden D. Antiphospholipid antibodies and recurrent abortion. Obstet Gynecol 1991;77:854.
84. Grandone E, Margaglione M, Vecchione G. Antiphospholipid antibodies and risk of fetal loss: a pilot report of a cross-sectional study [Abstract]. Thromb Haemost 1993;69:597.
85. Birdsall M, Pattison N, Chamley L. Antiphospholipid antibodies in pregnancy. Aust NZ J Obstet Gynaecol 1992;32:328.
86. Maclean MA, Cumming GP, McCall F. The prevalence of lupus anticoagulant and anticardiolipin antibodies in women with a history of first trimester miscarriages. Br J Obstet Gynaecol 1994; 101:103.
87. Howard MA, Firkin BG, Healy DL. Lupus anticoagulant in a woman with multiple spontaneous miscarriage. Am J Hematol 1987;26:175.
88. Taylor M, Cauchi MN, Buchanan RRC. The lupus anticoagulant, anticardiolipin antibodies, and recurrent miscarriage. Am J Reprod Immunol 1990;23:33.
89. Parke AL, Wilson D, Maier D. The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortion, women with successful pregnancies, and women who have never been pregnant. Arthritis Rheum 1991;34:1231.
90. Kochenour NK, Branch DW, Rote NS. A new postpartum syndrome associated with antiphospholipid antibodies. Obstet Gynecol 1987;69:460.
91. Intrator L, Oksenhendler E, Desforges L. Anticardiolipin antibodies in HIV infected patients with or without immune thrombocytopenic purpura. Br J Haematol 1988;67:269.
92. Canoso RT, Zon LI, Groopman JE. Anticardiolipin antibodies associated with HTLV-III Infection. Br J Haematol 1987;65:495.
93. Panzer S, Stain C, Hartl H. Anticardiolipin antibodies are elevated in HIV-I infected haemophiliacs but do not predict for disease progression. Thromb Haemost 1989;61:81.
94. Stimmler MM, Quismorio FP, McGehee WG. Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch Intern Med 1989;149:1833.
95. Vaarala O, Palosuo T, Kleemola M. Anticardiolipin response in acute infections. Clin Immunol and Immuopathol 1986;41:8.
96. Violi F, Ferro D, Quintarelli C. Dilute aPTT prolongation by antiphospholipid antibodies in patients with liver cirrhosis. Thromb Haemost 1990;63:183.
97. Harrison RL, Alperin JB, Kumar D. Concurrent lupus anticoagulants and prothrombin deficiency due to phenytoin use. Arch Pathol Lab Med 1987;111:719.
98. Lillicrap DP, Pinto M, Benford K. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with clorpromazine and other phenothiazines. Am J Clin Pathol 1990;93:771.
99. Conley CL, Hartmann RC. A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J Clin Invest 1952;31:621.
100. Criel A, Collen D, Masson PL. A case of IgM antibodies which inhibit the contact activation of blood coagulation. Thromb Res 1978;12:883.
101. Kunkel L. Acquired circulating anticoagulants. Hematol Oncol Clin North Am 1992;6:1341.
102. Coller BS, Hultin MB, Hoyer LW. Normal pregnancy in a patient with a prior postpartum factor VIII inhibitor: With observations on pathogenesis and prognosis. Blood 1981;58:619.
103. LeFrere JJ, Gozin D, Lerable J. Circulating anticoagulant in asymptomatic persons seropositive for human immunodeficiency virus [letter]. Ann Intern Med 1988;108:771.
104. Taillan B, Roul C, Fuzibet JG. Circulating anticoagulant in patients seropositive for human immunodeficiency virus. Ann Intern Med 1989:87:405.
105. Davis S, Furie B, Griffin JH. Circulating inhibitors of blood coagulation associated with procainamide-induced lupus anticoagulants. Am J Hematol 1978;4:401.
106. Jeffrey RF. Transient lupus anticoagulant with fansidar therapy. Postgrad Med J 1986;62:893.
107. Morgan M, Downs K, Chesterman CN, et al. Clinical analysis of 125 patients with the lupus anticoagulant. Aust NZ J Med 1993; 23:151.
108. Bick RL, Ucar K. Hypercoagulability and Thrombosis. Hematol Oncol Clin North Am 1992;6:1421.
109. Schleider MA, Nachman RL, Jaffe EA. A clinical study of the lupus anticoagulant. Blood 1976;48:499.
110. Regan MG, Lackner H, Karpatkin S. Platelet function and coagulation profile in lupus erythematosus. Ann Intern Med 1974;81: 462.
111. Mueh JR, Herbst KD, Rapaport SI. Thrombosis in patients with the "lupus"-type circulating anticoagulant. Ann Intern Med 1980;92:156.
112. Shapiro SS, Siegel KJE. Hemorrhagic disorders associated with circulating anticoagulants. In: Ratnoff OD, Forbes CD, eds. Disorders of hemostasis. Philadelphia: W.B. Saunders, 1991:245.
113. Kleinknecht D, Bobrie G, Meyer O, et al. Recurrent thrombosis and renal vascular disease in a patient with lupus anticoagulant. Nephron Dial Transplant 1989;4:854.
114. Pope JM, Canny CL, Bell DA. Cerebral ischemic events associated with endocarditis, retinal vascular disease and lupus anticoagulant. Am J Med 1991;90:299.
115. Reyes H, Dearing L, Shoenfeld Y. Antiphospholipid antibodies: A critique of their heterogeneity and hegemony. Semin Thromb Hemost 1994;20:89.
116. Kaczor NA, Bickford NN, Triplett DA. Evaluation of different mixing study reagents and dilution effect in lupus anticoagulant testing. J Clin Pathol 1991;95:408.
117. Ko J, Guaglianone P, Wolin M, et al. Variation in the sensitivity of an activated thromboplastin time reagent to the lupus anticoagulant [Abstract]. Am J Clin Pathol 1993;99:333.
118. Bick RL. The Antiphospholipid Thrombosis Syndromes: Fact, Fiction, Confusion & Controversy. Am J Clin Pathol 1993;100:477.
119. Thiagarajan P, Pengo V, Shapiro SS. The use of the dilute Russel viper venom time for the diagnosis of lupus anticoagulants. Blood 1986;68:869.
120. McGehee WG, Patch MJ, Lingao JU. Detection of the lupus anticoagulant: a comparison of the kaolin clotting time with the tissue thromboplastin inhibition test [Abstract]. Blood 1983;62 (suppl):276a.
121. Rosove MH, Ismail M, Koziol BJ. Lupus anticoagulants: Improved diagnosis with a kaolin clotting time using rabbit brain phospholipid in standard and high concentrations. Blood 1986; 68:472.
122. Bick RL. Hypercoagulability and Thrombosis. In: Disorders of thrombosis and hemostasis: Clinical and laboratory practice. Chicago: ASCP Press, 1992:261.
123. Harris EN. Immunology of antiphospholipid antibodies. In: Lahita R. ed. Systemic lupus erythematosus, 2nd ed. London: Churchill Livingstone, 1992:305.
124. Rauch J, Janoff AS. The nature of antiphospholipid antibodies. J Rheumatol 1992;19:1782.
125. De Castellarnau C, Vila CL, Sancho MJ. Lupus anticoagulant, recurrent abortion, and prostacyclin production by cultured smooth muscle cells. Lancet 1983;2:1137.
126. Sanfelippo MJ, Drayna CJ. Prekallikrein inhibition associated with the lupus anticoagulant: A mechanism for thrombosis. Am J Clin Pathol 1982;77:275.
127. Bick RL. The Antiphospholipid Thrombosis (APL-T) Syndromes: Characteristics and recommendations for classification and treatment. Am J Clin Pathol 1991;96:424.
128. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303.
129. Schved JF, Dupuy-Fons C, Biron C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: The Montpellier Antiphospholipid (MAP) Study. Haemostasis 1994; 24:175.
130. Vila P, Hernandez MC, Lopez-Fernandez MF. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994;72:209.
131. Bick RL, Baker WF. Deep Vein Thrombosis: Prevalence of etiologic factors and results of management in 100 consecutive patients. Semin Thromb Hemost 1992;18:267.
132. Bick RL, Ancypa D. The antiphospholipid and thrombosis syndromes: Clinical and laboratory correlates. Clin Lab Med 1995; 15:63.
133. Falcon CR, Hoffer AM, Forastiero RR, et al. Clinical significance of various ELISA assays for detecting antiphospholipid antibodies. Thromb Haemost 1990;64:21.
134. Loizou S, McCrea JD, Rudge AC, et al. Measurement of anticardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantitation of results. Clin Exp Immunol 1985;62:738.
135. Falcon CR, Hoffer AM, Carreras LO. Antiphosphatidylinositol antibodies as markers of the antiphospholipid syndrome. Thromb Haemost 1990;63:321.
136. Reyes H, Dearing L, Bick RL, et al. Laboratory diagnosis of antiphospholipid syndromes, Clin Lab Med 1995;15:85.
137. Triplett DA. Laboratory evaluation of circulating anticoagulants. In: Bick RL, Bennett RM, Brynes RK, et al., eds. Hematology: Clinical and laboratory practice. St. Louis: C.V. Mosby, 1993:1539.
138. Mannucci PM, Canciani MT, Mari D, et al. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus-like inhibitor. Scand J Haematol 1979;22:423.
139. Bick RL, Pascoe HR, Laughlin WR. Efficacy of four common activated partial thromboplastin times in screening for the lupus anticoagulant [Abstract]. Blood 1994;84:82.
140. Saxena R, Saraya AK, Kotte VK, et al. Evaluation of four coagulation tests to detect plasma lupus anticoagulants. Am J Clin Pathol 1991;96:755.
141. Exner T, Triplett DA, Taberner D, et al. Guidelines for testing and revised criteria for lupus anticoagulants. Thromb Haemost 1991; 65:320.
142. Bell HG, Alton HG. A brain extract as a substitute for platelet suspensions in the thromboplastin generation test. Nature 1954; 174:880.
143. Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemost 1989;62:892.